In addition, it is possible that targeting CRP use to children for which risk of bacterial infection is determined to be low or intermediate after initial clinical assessment, as opposed to all comers with ARI, may maximize its cost-effectiveness [30,31,58]. Here, CRP is linked to bacterial infectious disease.